稳定胸痛患者无创心血管检查的预后价值:PROMISE试验解读
CTA组正常结果比例更低而事件率更高,非阻塞性冠心病占CTA组事件的54.0%,CTA对事件的判别能力优于功能检查。
要点
- CTA组33.4%结果正常,功能检查组78.0%结果正常,两组事件率分别为0.9%与2.1%。
- CTA组54.0%事件(74/137)发生于非阻塞性冠心病(1%-69%狭窄)患者。
- CTA判别能力c-index 0.72优于功能检查0.64,P=0.04。
核心结论
- 冠状动脉CTA通过识别非阻塞性冠心病高危患者,在阻塞性冠心病、心肌缺血及事件负担低的当代稳定胸痛患者中提供优于功能检查的预后信息。
研究设计与样本
- PROMISE试验将稳定胸痛且阻塞性冠心病验前概率中等的患者随机分配至功能检查(运动心电图、核素负荷试验或负荷超声心动图)或冠状动脉CTA,基于现场诊断报告分为正常、轻度、中度或重度异常,主要终点为死亡、心肌梗死或不稳定型心绞痛住院,中位随访26.1个月。
- 随机分配至CTA者4500例,随机分配至功能检查者4602例。
主要发现
- CTA组正常结果比例33.4% vs 功能检查组78.0%,事件发生率0.9% vs 2.1%,两者P<0.001。
- CTA组54.0%事件(n=74/137)发生于非阻塞性冠心病(1%-69%狭窄)患者。
- 阻塞性冠心病与心肌缺血患病率分别为11.9%与12.7%,预后价值相似(HR 3.74,95%CI 2.60-5.39;HR 3.47,95%CI 2.42-4.99)。
- 以正常检查为参照,CTA轻度、中度、重度异常的事件HR分别为2.94、7.67、10.13(均P<0.001);功能检查相应类别HR分别为0.94(P=0.87)、2.65(P=0.001)、3.88(P<0.001)。
- CTA预测事件的判别能力优于功能检查(c-index 0.72,95%CI 0.68-0.76 vs 0.64,95%CI 0.59-0.69;P=0.04)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Optimal management of patients with stable chest pain relies on the prognostic information provided by noninvasive cardiovascular testing, but there are limited data from randomized trials comparing anatomic with functional testing. METHODS: In the PROMISE trial (Prospective Multicenter Imaging Study for Evaluation of Chest Pain), patients with stable chest pain and intermediate pretest probability for obstructive coronary artery disease (CAD) were randomly assigned to functional testing (exercise electrocardiography, nuclear stress, or stress echocardiography) or coronary computed tomography angiography (CTA). Site-based diagnostic test reports were classified as normal or mildly, moderately, or severely abnormal. The primary end point was death, myocardial infarction, or unstable angina hospitalizations over a median follow-up of 26.1 months. RESULTS: Both the prevalence of normal test results and incidence rate of events in these patients were significantly lower among 4500 patients randomly assigned to CTA in comparison with 4602 patients randomly assigned to functional testing (33.4% versus 78.0%, and 0.9% versus 2.1%, respectively; both P<0.001). In CTA, 54.0% of events (n=74/137) occurred in patients with nonobstructive CAD (1%-69% stenosis). Prevalence of obstructive CAD and myocardial ischemia was low (11.9% versus 12.7%, respectively), with both findings having similar prognostic value (hazard ratio, 3.74; 95% confidence interval [CI], 2.60-5.39; and 3.47; 95% CI, 2.42-4.99). When test findings were stratified as mildly, moderately, or severely abnormal, hazard ratios for events in comparison with normal tests increased proportionally for CTA (2.94, 7.67, 10.13; all P<0.001) but not for corresponding functional testing categories (0.94 [P=0.87], 2.65 [P=0.001], 3.88 [P<0.001]). The discriminatory ability of CTA in predicting events was significantly better than functional testing (c-index, 0.72; 95% CI, 0.68-0.76 versus 0.64; 95% CI, 0.59-0.69; P=0.04). If 2714 patients with at least an intermediate Framingham Risk Score (>10%) who had a normal functional test were reclassified as being mildly abnormal, the discriminatory capacity improved to 0.69 (95% CI, 0.64-0.74). CONCLUSIONS: Coronary CTA, by identifying patients at risk because of nonobstructive CAD, provides better prognostic information than functional testing in contemporary patients who have stable chest pain with a low burden of obstructive CAD, myocardial ischemia, and events. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01174550.
引用
- Hoffmann U, Ferencik M, Udelson JE, et al. Prognostic Value of Noninvasive Cardiovascular Testing in Patients With Stable Chest Pain: Insights From the PROMISE Trial (Prospective Multicenter Imaging Study for Evaluation of Chest Pain). Circulation. 2017. PMID: 28389572. doi:10.1161/CIRCULATIONAHA.116.024360
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。